The guideline base the diagnosis of MAFLD on the detection of fatty liver in conjunction with at least one of three criteria: overweight/obesity, T2DM, or clinical evidence of metabolic dysfunction (including waist circumference, blood pressure, blood lipids, blood glucose, HOMA-IR, hS-CRP, etc.). This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.